Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
Jonathan’s Long Life Gives Longevity Research a Clue That Still Needs Testing
A genomic study of a tortoise estimated to be 194 years old highlights stable gene regulation. Exceptional survival provides hypotheses, rather than a treatment.
-
Orca-T Enters Commercial Use by Redesigning the Donor Graft
The first reported commercial Orca-T transplant marks a move from clinical trials into practice. Its innovation lies in controlling the balance of donor cells.
-
AlphaGenome Can Read DNA’s Control Signals, but a Prediction Still Needs an Experiment
AI can help rank DNA changes outside protein-coding genes. Turning that ranking into a disease mechanism or therapy requires additional evidence.
-
A Cell That Stops Dividing Can Still Push Its Neighbours Toward Cancer Spread
A 2026 laboratory and animal study shows why senescence must be understood as a change in cellular behaviour, rather than a simple shutdown.
-
Masked Immunotherapy Tries to Separate a Cancer Attack From Its Collateral Damage
VIR-5500 has received FDA Fast Track designation. Its larger test is whether a protective molecular mask can make immune attacks more selective in solid tumours.
-
RNA Editing Moves Toward a Larger Trial Without Rewriting DNA
Wave has outlined a possible registrational path for WVE-006 in alpha-1 antitrypsin deficiency. The RNA editor remains investigational in an early human trial.
-
FDA Approval Brings Immunotherapy Into Post-Surgery Care for dMMR Colon Cancer
Atezolizumab plus chemotherapy is now FDA-approved after surgery for a defined group with stage III colon cancer. The ATOMIC trial measured recurrence or death.
-
An Ageing-on-a-Chip Model Compresses Decades of Signals Into Four Days
A linked fat-and-liver tissue chip reacted to serum from older donors within four days. It models ageing-related signals; it does not reverse ageing in people.
-
Gene Editing Shielded Donor Marrow From a Leukaemia Drug, but the Trial Ended Early
A Phase I/II study edited CD33 out of donor blood-forming stem cells before an antibody-drug treatment. The trial generated safety data but ended early.
-
Fast Track Does Not Mean Approval for a Lead-212 Cancer Therapy
PSV359 has FDA Fast Track designation for a rare sarcoma. The radioactive drug remains investigational in a recruiting Phase I/IIa trial.
-
Engineered tRNA Medicines Target Genetic Disease at the Protein Assembly Line
Two 2026 developments show how engineered tRNA could bypass premature stops in protein production. A mouse gene-therapy study and an early clinical programme remain distinct.
-
An Armoured CAR T Therapy Begins Its First Human Test Against Ovarian Cancer
GB-5267 has reached a first-in-human ovarian cancer trial. Its IL-18 design, delivery plan and AI-assisted engineering now face a clinical safety test.